MCID: BRN028
MIFTS: 75

Brain Cancer

Categories: Cancer diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Brain Cancer

MalaCards integrated aliases for Brain Cancer:

Name: Brain Cancer 12 55 15
Malignant Neoplasm of Brain 29 72 33
Adult Brain Tumor 12 55 72
Brain Neoplasms 75 44 72
Primary Malignant Neoplasm of Brain 12 72
Neoplasm of Brain 12 6
Brain Neoplasm 12 17
Brain Tumors 55 43
Malignant Primary Brain Neoplasm 12
Adult Malignant Brain Neoplasm 12
Malignant Tumor of Adult Brain 12
Malignant Primary Brain Tumors 55
Malignant Primary Brain Tumor 12
Malignant Tumor of Brain 12
Malignant Brain Tumour 12
Primary Brain Neoplasm 12
Brain Neoplasm, Adult 12
Primary Brain Tumors 15
Brain Tumor, Primary 72
Primary Brain Tumor 12
Brain Tumor Primary 55
Tumor of the Brain 12
Brain Tumor, Adult 53
Bt - Brain Tumour 12
Cancer, Brain 40

Classifications:



External Ids:

Disease Ontology 12 DOID:1319
ICD9CM 35 191 191.9 239.6
MeSH 44 D001932
SNOMED-CT 68 93727008
ICD10 33 C71 C71.9
UMLS 72 C0006118 C0153633 C0220624 more

Summaries for Brain Cancer

MedlinePlus : 43 A brain tumor is a growth of abnormal cells in the tissues of the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Some are primary brain tumors, which start in the brain. Others are metastatic, and they start somewhere else in the body and move to the brain. Brain tumors can cause many symptoms. Some of the most common are Headaches, often in the morning Nausea and vomiting Changes in your ability to talk, hear, or see Problems with balance or walking Problems with thinking or memory Feeling weak or sleepy Changes in your mood or behavior Seizures Doctors diagnose brain tumors by doing a neurologic exam and tests including an MRI, CT scan, and biopsy. Treatment options include watchful waiting, surgery, radiation therapy, chemotherapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Many people get a combination of treatments. NIH: National Cancer Institute

MalaCards based summary : Brain Cancer, also known as malignant neoplasm of brain, is related to li-fraumeni syndrome and brain glioma, and has symptoms including seizures, tremor and back pain. An important gene associated with Brain Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are TGF-Beta Pathway and Regulation of lipid metabolism Insulin signaling-generic cascades. The drugs Tramadol and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, lung and breast, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.

Wikipedia : 75 A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors:... more...

Related Diseases for Brain Cancer

Diseases related to Brain Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1088)
# Related Disease Score Top Affiliating Genes
1 li-fraumeni syndrome 34.2 TP53 PTEN IDH1 EGFR
2 brain glioma 33.6 TP53 NES MGMT IDH1 EGFR
3 medulloblastoma 33.5 TP53 SMARCB1 PTEN PIK3CA NRAS NES
4 gliomatosis cerebri 33.2 TP53 PTEN NES IDH1 EGFR
5 supratentorial cancer 33.1 TP53 PTEN NES MGMT IDH2 IDH1
6 infratentorial cancer 33.0 TP53 SMARCB1 NES
7 lung cancer 32.6 TP53 PTEN PIK3CA NRAS MGMT ENO2
8 glioblastoma multiforme 32.6 TP53 PTEN PIK3CA NES MGMT IDH1
9 glioblastoma 32.3 TP53 PTEN PIK3CA NRAS MIR25 MGMT
10 glioma 32.2 TP53 PTEN PIK3CA MIR25 IDH2 IDH1
11 cerebral ventricle cancer 31.9 TP53 SMARCB1 ENO2
12 giant cell glioblastoma 31.9 TP53 PTEN MGMT IDH1 EGFR BRAF
13 meningioma, familial 31.9 TP53 SMARCB1 PTEN ENO2
14 pleomorphic xanthoastrocytoma 31.9 TP53 SMARCB1 MGMT IDH1 BRAF
15 oligodendroglioma 31.8 TP53 PTEN MGMT IDH2 IDH1 ENO2
16 ewing sarcoma 31.8 TP53 NES ENO2 EGFR BMI1 ALK
17 small cell carcinoma 31.7 TP53 PTEN ENO2 EGFR
18 gemistocytic astrocytoma 31.7 PTEN IDH2
19 cerebellar astrocytoma 31.7 TP53 IDH1
20 carcinosarcoma 31.6 TP53 PTEN PIK3CA
21 protoplasmic astrocytoma 31.6 TP53 IDH2
22 nervous system cancer 31.6 TP53 SMARCB1 PTEN NES MGMT IDH2
23 neurilemmoma 31.5 SMARCB1 NES ENO2
24 central nervous system cancer 31.5 TP53 SMARCB1 PTEN NES MGMT IDH2
25 transitional cell carcinoma 31.5 TP53 PTEN ENO2 EGFR BRAF
26 colorectal cancer 31.5 TP53 PTEN PIK3CA NRAS MIR25 MGMT
27 intrahepatic cholangiocarcinoma 31.5 TP53 IDH2 IDH1 EGFR
28 ependymoma 31.5 NES MGMT ENO2 EGFR
29 anaplastic oligodendroglioma 31.5 MGMT IDH2 EGFR
30 ganglioglioma 31.4 TP53 SMARCB1 NES ENO2 BRAF
31 myelodysplastic syndrome 31.4 TP53 PTPN11 NRAS IDH2 IDH1 BMI1
32 glioma susceptibility 1 31.4 TP53 IDH2 IDH1
33 cholangiocarcinoma 31.4 TP53 PTEN PIK3CA IDH2 IDH1 EGFR
34 hydrocephalus 31.4 TP53 PTEN NES ENO2
35 myeloma, multiple 31.3 TP53 PTPN11 NRAS MIR25 IDH2 IDH1
36 fibrillary astrocytoma 31.3 TP53 MGMT IDH2 IDH1
37 medullomyoblastoma 31.2 TP53 SMARCB1 ENO2
38 brain stem glioma 31.2 TP53 PIK3CA IDH2 IDH1 EGFR BRAF
39 grade iii astrocytoma 31.2 TP53 PTEN MGMT IDH2 EGFR DMBT1
40 rhabdoid cancer 31.2 TP53 SMARCB1 ENO2
41 small cell cancer of the lung 31.2 TP53 PTEN PIK3CA ENO2 EGFR
42 squamous cell carcinoma, head and neck 31.2 TP53 PTEN PIK3CA IDH2 EGFR BRAF
43 breast adenocarcinoma 31.2 TP53 PTEN PIK3CA EGFR
44 undifferentiated pleomorphic sarcoma 31.2 PIK3CA IDH2 IDH1
45 lynch syndrome 31.2 TP53 MGMT EGFR BRAF
46 optic nerve glioma 31.1 TP53 NES ENO2
47 erdheim-chester disease 31.1 PIK3CA NRAS BRAF
48 teratoma 31.1 TP53 NES ENO2
49 gliosarcoma 31.1 TP53 PTEN NES MGMT IDH1 ENO2
50 intracranial chondrosarcoma 31.1 TP53 IDH2 IDH1

Comorbidity relations with Brain Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Brain Edema
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Hypertension, Essential
Obstructive Hydrocephalus Schizophreniform Disorder

Graphical network of the top 20 diseases related to Brain Cancer:



Diseases related to Brain Cancer

Symptoms & Phenotypes for Brain Cancer

UMLS symptoms related to Brain Cancer:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Brain Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.96 EGFR PIK3CA
2 Decreased viability GR00221-A-1 9.96 ALK EGFR NRAS PIK3CA SMARCB1
3 Decreased viability GR00221-A-2 9.96 PIK3CA SMARCB1
4 Decreased viability GR00221-A-3 9.96 NRAS SMARCB1
5 Decreased viability GR00221-A-4 9.96 ALK EGFR PIK3CA
6 Decreased viability GR00381-A-1 9.96 SMARCB1
7 Decreased viability GR00402-S-2 9.96 ALK EGFR NRAS PIK3CA SMARCB1
8 Decreased cell migration GR00055-A-1 9.65 ALK BRAF EGFR EPHB2 PIK3CA
9 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 EGFR EPHB2 NRAS PTEN PTPN11
10 Reduced mammosphere formation GR00396-S 9.17 BRAF EGFR IDH2 NRAS PTEN PTPN11

MGI Mouse Phenotypes related to Brain Cancer:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 BRAF DMBT1 EGFR ENO2 EPHB2 NRAS
2 growth/size/body region MP:0005378 10.29 ALK BRAF EGFR ENO2 EPHB2 IDH1
3 homeostasis/metabolism MP:0005376 10.26 ALK BRAF DMBT1 EGFR IDH1 MGMT
4 endocrine/exocrine gland MP:0005379 10.22 ALK BRAF EGFR EPHB2 MGMT NRAS
5 mortality/aging MP:0010768 10.22 ALK BRAF DMBT1 EGFR EPHB2 IDH1
6 digestive/alimentary MP:0005381 10.2 BRAF DMBT1 EGFR EPHB2 NRAS PTEN
7 embryo MP:0005380 10.19 BRAF DMBT1 EGFR NRAS PIK3CA PTEN
8 neoplasm MP:0002006 10.15 ALK BRAF DMBT1 EGFR IDH2 MGMT
9 craniofacial MP:0005382 10.1 BRAF EGFR ENO2 EPHB2 NRAS PTPN11
10 integument MP:0010771 10.06 ALK BRAF EGFR NRAS PIK3CA PTEN
11 liver/biliary system MP:0005370 9.98 BRAF EGFR NRAS PTEN PTPN11 SMARCB1
12 hearing/vestibular/ear MP:0005377 9.97 BRAF DMBT1 EGFR EPHB2 PTPN11 TP53
13 reproductive system MP:0005389 9.91 ALK BRAF EGFR EPHB2 PIK3CA PTEN
14 pigmentation MP:0001186 9.87 ALK BRAF EGFR NRAS PTEN PTPN11
15 respiratory system MP:0005388 9.81 ALK BRAF EGFR ENO2 IDH1 MGMT
16 skeleton MP:0005390 9.61 ALK BRAF EGFR IDH1 NRAS PIK3CA
17 vision/eye MP:0005391 9.32 ALK BRAF EGFR EPHB2 NRAS PIK3CA

Drugs & Therapeutics for Brain Cancer

Drugs for Brain Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 689)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
2
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
4
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
5
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
6
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
7
Ephedrine Approved Phase 4 299-42-3 9294
8
Phenylephrine Approved Phase 4 59-42-7 6041
9
Pseudoephedrine Approved Phase 4 90-82-4 7028
10
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
11
Thrombin Approved, Investigational Phase 4
12
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
13
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
14
Cabergoline Approved Phase 4 81409-90-7 54746
15
Labetalol Approved Phase 4 36894-69-6 3869
16
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
17
Clevidipine Approved, Investigational Phase 4 167221-71-8
18
Hydralazine Approved Phase 4 86-54-4 3637
19
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
20
Memantine Approved, Investigational Phase 4 19982-08-2 4054
21
Donepezil Approved Phase 4 120014-06-4 3152
22
Propranolol Approved, Investigational Phase 4 525-66-6 4946
23
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
24
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
25
Amitriptyline Approved Phase 4 50-48-6 2160
26
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
27
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
28
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
29
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
30
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
31
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
32
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
33
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
34
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
35
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
36
Conivaptan Approved, Investigational Phase 4 210101-16-9 151171
37
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
38
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
39 Central Nervous System Stimulants Phase 4
40 Neurotransmitter Uptake Inhibitors Phase 4
41 Dopamine Uptake Inhibitors Phase 4
42 Cytochrome P-450 CYP3A Inhibitors Phase 4
43 Cytochrome P-450 Enzyme Inhibitors Phase 4
44 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Phase 4
45 Excitatory Amino Acid Agonists Phase 4
46 Hemostatics Phase 4
47 Coagulants Phase 4
48 Vasoconstrictor Agents Phase 4
49 14-alpha Demethylase Inhibitors Phase 4
50 Steroid Synthesis Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 1721)
# Name Status NCT ID Phase Drugs
1 Effect of Single Dose of Tramadol on Extubation Response and Quality of Emergence(Cough and Nausea Vomiting) Following Supratentorial Intracranial Surgery Unknown status NCT02964416 Phase 4 Injection Tramadol
2 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
3 Use of Integrated PET/MR to Evaluate Clinical Staging and Monitor Treatment Response of Neoadjuvant Chemotherapy for Breast Cancer Patients: A Pilot Study Unknown status NCT02766530 Phase 4
4 Prospective Trial of Intravenous Levetiracetam in Patients With Primary Brain Tumors and at Least One Symptomatic Seizure Who Undergo Biopsy or Cytoreductive Surgery (HELLO-study) Completed NCT00571155 Phase 4 levetiracetam
5 Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed NCT02034708 Phase 4 Dotarem®;Gadovist®/Gadavist®
6 Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
7 A Prospective, Randomized Trial Comparing Surgery Versus Radiosurgery for the Treatment of Metastatic Brain Tumors Completed NCT00075166 Phase 4
8 Sugammadex Given for the Reversal of Deep Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants: A Retrospective Study Completed NCT02708056 Phase 4 Sugammadex
9 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
10 A Randomized, Open Label, Two-way Crossover, Single Dose Bioequivalence Study Comparing Dralitem® Capsules to the Reference Drug Temodal® Capsules in Patients With Primary Tumors of the Central Nervous System Under Fasting Conditions Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
11 Influence of Vasopressors on Brain Oxygenation and Microcirculation in Anesthetized Patients With Cerebral Tumors Completed NCT02713087 Phase 4 Ephedrine;Phenylephrine
12 Phase IV, Double-Blind, Multi-Center, Randomized, Cross-Over Study to Compare 0.10 Mmol/kg of MultiHance With 0.10 Omniscan in Magnetic Resonance Imaging (MRI) of the Brain Completed NCT00323102 Phase 4 Multihance
13 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
14 A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T Completed NCT00395863 Phase 4 Multihance;Arm 2 - Magnevist
15 A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
16 Phase IV, Double-blind, Multi-center, Randomized, Crossover Study to Compare 0.1 mmol/kg of Prohance® With 0.1 mmol/kg of Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain (TRUTH) Completed NCT01613417 Phase 4 gadoteridol;gadobutrol
17 The Effect of Pre-incisional Anterior Scalp Block on Intraoperative Opioid Consumption in Adult Patients Undergoing Elective Craniotomy to Remove Tumor: A Prospective Randomized Controlled Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
18 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
19 The Effect of Dexmedetomidine as an Adjuvant to General Anesthesia on Intelligence Development in Pediatric Patients Undergoing Craniotomy: a Randomized, Double-blind and Placebo-controlled Pilot Trial Completed NCT02810899 Phase 4 dexmedetomidine;normal saline
20 The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block: A Randomized Controlled Trial Completed NCT02558569 Phase 4 Levobupivacaine
21 The Effect of Intravenous Single Dose of Magnesium Sulphate on Attenuation of Hemodynamic Pressor Response After Myfield's Clamp Application During Craniotomies Completed NCT03318471 Phase 4 MgSo4;0.9% NaCl
22 Validation and Verification of 3 Dimensional Laparoscopic System in Laparoscopic Distal Pancreatectomy & Splenectomy Completed NCT02757690 Phase 4
23 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
24 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
25 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
26 A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial Recruiting NCT02334722 Phase 4 Levetiracetam extended release
27 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
28 Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
29 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
30 GCSF Plus Plerixafor as First-line Treatment for Autologous Stem Cells Harvest in Children With Malignant Diseases in Need for High-dose Chemotherapy With Stem Cell Rescue. Not yet recruiting NCT02006225 Phase 4 Plerixafor
31 Phase IV GliaSite® Radiation Therapy System Registry Protocol for the Treatment of Resectable Malignant Brain Tumors Terminated NCT00415467 Phase 4
32 Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients Terminated NCT00727090 Phase 4 Conivaptan
33 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Terminated NCT02028325 Phase 4 Fluorescein Sodium
34 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
35 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
36 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
37 Role of 3-D Navigable Ultrasound in Resection of Intra-axial Brain Tumors - A Randomized Controlled Study Unknown status NCT02150564 Phase 3
38 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
39 Barrow 5-ALA Intraoperative Confocal Evaluation Trial Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
40 Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas Unknown status NCT00689715 Phase 2, Phase 3
41 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
42 Comparison of Esmolol and Dexmedetomidine on Sympathetic Control During Intracranial Procedures Unknown status NCT02563288 Phase 3 Esmolol;Dexmedetomidine
43 Gefitinib Alone or With Concomitant Whole Brain Radiotherapy for Patients Harboring an EGFR Mutation With Multiple Brain Metastases From Non-Small-cell Lung Cancer: a Phase II/III Randomized Controlled Trial Unknown status NCT02338011 Phase 2, Phase 3 Gefitinib
44 Phase 3 Study of Stereotactic Radiotherapy of the Postoperative Resection Cavity Versus Whole-Brain Irradiation After Surgical Resection of Single Brain Metastasis Unknown status NCT01535209 Phase 3
45 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Effective on Erlotinib or Gefitinib(RT1001) Unknown status NCT01158170 Phase 3 Erlotinib /Gefitinib
46 A Randomized Trial of Robotic Compared to Fixed Gantry Radiosurgery for Brain Metastases Unknown status NCT01353573 Phase 3
47 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
48 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
49 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
50 Intra-individual Comparison Study of Intravenously Administered Magnevist (SH L 451A) on Lesion Detection Ability in MRI After an Initial Dose of 0.1 mmol/kg and After an Additional Dose of 0.1 mmol/kg in Patients With Metastatic Brain Tumor Completed NCT00681551 Phase 3 Magnevist (SH L 451A);Magnevist (SH L 451A)

Search NIH Clinical Center for Brain Cancer

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Carmustine
Etoposide
etoposide phosphate
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Lomustine
Lomustine
Mifepristone
peginterferon alfa-2a
peginterferon alfa-2b
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Cochrane evidence based reviews: brain neoplasms

Genetic Tests for Brain Cancer

Genetic tests related to Brain Cancer:

# Genetic test Affiliating Genes
1 Malignant Neoplasm of Brain 29

Anatomical Context for Brain Cancer

MalaCards organs/tissues related to Brain Cancer:

41
Brain, Lung, Breast, T Cells, Testes, Endothelial, Bone

Publications for Brain Cancer

Articles related to Brain Cancer:

(show top 50) (show all 3544)
# Title Authors PMID Year
1
Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. 17
31366516 2019
2
Differentiation of postoperative changes and residual tumors in dynamic contrast-enhanced sella MRI after transsphenoidal resection of pituitary adenoma. 17
31277105 2019
3
Differential circular RNA expression profiles of invasive and non-invasive non-functioning pituitary adenomas: A microarray analysis. 17
31261542 2019
4
Survey of MicroRNA expression in pediatric brain tumors. 88
21157891 2011
5
FasL gene knock-down therapy enhances the antiglioma immune response. 9 38
20406899 2010
6
Mig-6 controls EGFR trafficking and suppresses gliomagenesis. 9 38
20351267 2010
7
MRI-coupled fluorescence tomography quantifies EGFR activity in brain tumors. 9 38
20152724 2010
8
CMDS: a population-based method for identifying recurrent DNA copy number aberrations in cancer from high-resolution data. 9 38
20031968 2010
9
A review of studies on targeting interleukin 4 receptor for central nervous system malignancy. 9 38
19689300 2009
10
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. 9 38
19333229 2009
11
Therapeutic targeting of g-protein coupled receptor-mediated epidermal growth factor receptor transactivation in human glioma brain tumors. 9 38
18991757 2008
12
Somatic alterations in brain tumors. 9 38
18575738 2008
13
Gene expression profiling of metastatic brain cancer. 9 38
17611651 2007
14
Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. 9 38
17679463 2007
15
Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. 9 38
17483310 2007
16
Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor. 9 38
17440072 2007
17
Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. 9 38
17172420 2006
18
New roles for galectins in brain tumors--from prognostic markers to therapeutic targets. 9 38
15912884 2005
19
RNA interference and nonviral targeted gene therapy of experimental brain cancer. 9 38
15717065 2005
20
Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. 9 38
15173073 2004
21
Genetic polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the risk of adult brain tumors. 9 38
12540498 2003
22
Co-delivery of an antisense oligonucleotide and 5-fluorouracil using sustained release poly (lactide-co-glycolide) microsphere formulations for potential combination therapy in cancer. 9 38
11839444 2002
23
Ethnicity delineates different genetic pathways in malignant glioma. 9 38
11358811 2001
24
Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. 9 38
8700129 1996
25
Knockdown of lncRNA LSINCT5 suppresses growth and metastasis of human glioma cells via up-regulating miR-451. 38
31213092 2019
26
Genetic engineering and characterisation of chlorotoxin-fused gelonin for enhanced glioblastoma therapy. 38
30156929 2019
27
Targeting human brain cancer stem cells by curcumin-loaded nanoparticles grafted with anti-aldehyde dehydrogenase and sialic acid: Colocalization of ALDH and CD44. 38
31147008 2019
28
Cancer incidence among workers with blood lead measurements in two countries. 38
31296664 2019
29
Colloids or powders: Which nanoparticle formulations do cells like more? 38
31121380 2019
30
Genetic and genomic basis of the mismatch repair system involved in Lynch syndrome. 38
31273487 2019
31
Fear of disease progression in adult ambulatory patients with brain cancer: prevalence and clinical correlates. 38
30684045 2019
32
Synergistic combination of chemo‑phototherapy based on temozolomide/ICG‑loaded iron oxide nanoparticles for brain cancer treatment. 38
31436296 2019
33
Sprouty3 and Sprouty4, Two Members of a Family Known to Inhibit FGF-Mediated Signaling, Exert Opposing Roles on Proliferation and Migration of Glioblastoma-Derived Cells. 38
31374860 2019
34
Hospital Image Repair Strategies, Organizational Apology, and Medical Errors: An Analysis of the CoxHealth Brain Over-Radiation Case. 38
31394925 2019
35
IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma. 38
31371825 2019
36
Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population. 38
31383442 2019
37
The senses of the choroid plexus. 38
31404591 2019
38
Brain-targeted drug delivery by manipulating protein corona functions. 38
31395892 2019
39
Hypothalamic mTORC2 is essential for metabolic health and longevity. 38
31373126 2019
40
Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma. 38
31197598 2019
41
ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma: A Multidisciplinary Team-based, Multifactorial Analytical Approach. 38
31343422 2019
42
Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation. 38
31045274 2019
43
Systematic Evaluation of Transferrin-Modified Porous Silicon Nanoparticles for Targeted-Delivery of Doxorubicin to Glioblastoma. 38
31433156 2019
44
Tissue mechanics, an important regulator of development and disease. 38
31431174 2019
45
CT scan exposure in children with ventriculo-peritoneal shunts: single centre experience and review of the literature. 38
31428872 2019
46
Impact of Race and Socioeconomic Status on Psychologic Outcomes in Childhood Cancer Patients and Caregivers. 38
30629003 2019
47
Deep learning model integrating features and novel classifiers fusion for brain tumor segmentation. 38
31032544 2019
48
Glioblastoma Multiforme heterogeneity profiling with solid-state micropores. 38
31414186 2019
49
GDNFOS1 knockdown decreases the invasion and viability of glioblastoma cells. 38
31316623 2019
50
iClick Reactions of Square-Planar Palladium(II) and Platinum(II) Azido Complexes with Electron-Poor Alkynes: Metal-Dependent Preference for N1 vs N2 Triazolate Coordination and Kinetic Studies with 1H and 19F NMR Spectroscopy. 38
31393709 2019

Variations for Brain Cancer

ClinVar genetic disease variations for Brain Cancer:

6 (show top 50) (show all 237)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53): c.832C> A (p.Pro278Thr) single nucleotide variant Likely pathogenic,drug response rs17849781 17:7577106-7577106 17:7673788-7673788
2 TP53 NM_000546.5(TP53): c.818G> T (p.Arg273Leu) single nucleotide variant Pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
3 TP53 NM_000546.5(TP53): c.517G> T (p.Val173Leu) single nucleotide variant Pathogenic rs876660754 17:7578413-7578413 17:7675095-7675095
4 PTEN NM_000314.7(PTEN): c.1003C> T (p.Arg335Ter) single nucleotide variant Pathogenic rs121909231 10:89720852-89720852 10:87961095-87961095
5 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 17:7577539-7577539 17:7674221-7674221
6 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
7 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 17:7577547-7577547 17:7674229-7674229
8 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
9 PIK3CA NM_006218.4(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
10 BRAF NM_004333.6(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 7:140453136-140453136 7:140753336-140753336
11 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
12 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
13 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic rs587781288 17:7578508-7578508 17:7675190-7675190
14 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776
15 PIK3CA NM_006218.4(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic rs397517201 3:178936095-178936095 3:179218307-179218307
16 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic rs148924904 17:7578442-7578442 17:7675124-7675124
17 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic rs786201059 17:7577082-7577082 17:7673764-7673764
18 PTEN NM_000314.7(PTEN): c.517C> T (p.Arg173Cys) single nucleotide variant Pathogenic rs121913293 10:89711899-89711899 10:87952142-87952142
19 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic rs760043106 17:7578265-7578265 17:7674947-7674947
20 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic rs876659802 17:7577105-7577105 17:7673787-7673787
21 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic rs587782289 17:7577575-7577575 17:7674257-7674257
22 PIK3CA NM_006218.4(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 3:178952084-178952084 3:179234296-179234296
23 BRAF NM_004333.6(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 7:140453154-140453154 7:140753354-140753354
24 NRAS NM_002524.5(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
25 PIK3CA NM_006218.4(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
26 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
27 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
28 PTEN NM_000314.7(PTEN): c.388C> T (p.Arg130Ter) single nucleotide variant Pathogenic rs121909224 10:89692904-89692904 10:87933147-87933147
29 TP53 NM_000546.5(TP53): c.537T> G (p.His179Gln) single nucleotide variant Pathogenic rs876660821 17:7578393-7578393 17:7675075-7675075
30 TP53 NM_000546.5(TP53): c.712T> C (p.Cys238Arg) single nucleotide variant Pathogenic rs1057519981 17:7577569-7577569 17:7674251-7674251
31 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic rs730882005 17:7577568-7577568 17:7674250-7674250
32 NRAS NM_002524.5(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 1:115256528-115256528 1:114713907-114713907
33 NRAS NM_002524.5(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
34 IDH1 NM_005896.3(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 2:209113113-209113113 2:208248389-208248389
35 IDH1 NM_005896.3(IDH1): c.394C> G (p.Arg132Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 2:209113113-209113113 2:208248389-208248389
36 IDH1 NM_005896.3(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 2:209113113-209113113 2:208248389-208248389
37 IDH1 NM_005896.3(IDH1): c.395G> T (p.Arg132Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 2:209113112-209113112 2:208248388-208248388
38 TP53 NM_000546.5(TP53): c.731G> A (p.Gly244Asp) single nucleotide variant Pathogenic/Likely pathogenic rs985033810 17:7577550-7577550 17:7674232-7674232
39 TP53 NM_000546.5(TP53): c.730G> A (p.Gly244Ser) single nucleotide variant Pathogenic/Likely pathogenic rs1057519989 17:7577551-7577551 17:7674233-7674233
40 TP53 NM_000546.5(TP53): c.809T> C (p.Phe270Ser) single nucleotide variant Pathogenic/Likely pathogenic rs1057519986 17:7577129-7577129 17:7673811-7673811
41 TP53 NM_000546.5(TP53): c.845G> C (p.Arg282Pro) single nucleotide variant Pathogenic/Likely pathogenic rs730882008 17:7577093-7577093 17:7673775-7673775
42 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 17:7578407-7578407 17:7675089-7675089
43 PIK3CA NM_006218.4(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
44 PIK3CA NM_006218.4(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 3:178936091-178936091 3:179218303-179218303
45 ALK NM_004304.5(ALK): c.3575G> C (p.Arg1192Pro) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994089 2:29443642-29443642 2:29220776-29220776
46 ALK NM_004304.5(ALK): c.3383G> C (p.Gly1128Ala) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994088 2:29445450-29445450 2:29222584-29222584
47 ALK NM_004304.5(ALK): c.3824G> A (p.Arg1275Gln) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994087 2:29432664-29432664 2:29209798-29209798
48 PIK3CA NM_006218.4(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 3:178936093-178936093 3:179218305-179218305
49 PIK3CA NM_006218.4(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 3:178917478-178917478 3:179199690-179199690
50 TP53 NM_000546.5(TP53): c.818G> C (p.Arg273Pro) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802

Cosmic variations for Brain Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5673 CTNNB1 central nervous system,brain,primitive neuroectodermal tumour-medulloblastoma,classic c.98C>A p.S33Y 3:41224610-41224610 4

Copy number variations for Brain Cancer from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 112045 17 37800000 41900000 Gain Brain cancer
2 179187 8 123863081 124055936 Deletion RAF Brain cancer
3 205638 6 130400000 131300000 Deletion Brain cancer
4 233881 8 128747764 129113498 Amplification MYC Brain cancer
5 234173 8 131500000 139900000 Amplification KHDRBS3 Brain cancer
6 254105 9 51800000 140273252 Deletion Brain cancer

Expression for Brain Cancer

Search GEO for disease gene expression data for Brain Cancer.

Pathways for Brain Cancer

Pathways related to Brain Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.53 TP53 PTPN11 PIK3CA NRAS EPHB2 EGFR
2
Show member pathways
12.89 PTPN11 PTEN PIK3CA NRAS EGFR BRAF
3
Show member pathways
12.81 TP53 PTPN11 PTEN PIK3CA NRAS EGFR
4 12.76 TP53 PTEN PIK3CA NRAS EGFR BRAF
5
Show member pathways
12.72 PTPN11 PIK3CA NRAS EGFR BRAF
6
Show member pathways
12.68 TP53 PTPN11 PTEN PIK3CA NRAS EGFR
7
Show member pathways
12.67 TP53 PTPN11 PTEN PIK3CA NRAS BRAF
8
Show member pathways
12.58 TP53 PTPN11 PIK3CA NRAS EGFR
9
Show member pathways
12.58 TP53 SMARCB1 PTEN PIK3CA NRAS EGFR
10
Show member pathways
12.54 TP53 PTEN PIK3CA NRAS EGFR BRAF
11
Show member pathways
12.47 TP53 PTPN11 PIK3CA NRAS EGFR BRAF
12
Show member pathways
12.42 TP53 PIK3CA NRAS EGFR
13
Show member pathways
12.42 TP53 PTEN PIK3CA NRAS EGFR BRAF
14
Show member pathways
12.39 PTPN11 PIK3CA NRAS EGFR
15
Show member pathways
12.38 TP53 PTPN11 PTEN PIK3CA
16
Show member pathways
12.37 PIK3CA NRAS EPHB2 EGFR BRAF ALK
17
Show member pathways
12.37 PTPN11 PTEN PIK3CA NRAS BRAF
18
Show member pathways
12.31 PTPN11 PTEN PIK3CA NRAS
19
Show member pathways
12.26 PTPN11 PIK3CA NRAS BRAF
20
Show member pathways
12.24 TP53 PTPN11 NRAS BRAF
21 12.22 PTPN11 PIK3CA NRAS EPHB2
22 12.19 TP53 PTEN PIK3CA NRAS MIR25 EGFR
23 12.18 PTPN11 PTEN EGFR BRAF
24 12.16 TP53 PTEN PIK3CA NRAS
25
Show member pathways
12.16 TP53 PIK3CA NRAS BRAF
26 12.14 TP53 PTEN EGFR BRAF
27 12.09 TP53 PTEN PIK3CA NRAS EGFR
28
Show member pathways
12.09 PTPN11 PTEN PIK3CA NRAS EGFR
29 12.04 TP53 PTPN11 PIK3CA NRAS EGFR BRAF
30
Show member pathways
12.02 TP53 PIK3CA EGFR BRAF
31 12 TP53 PTEN PIK3CA NRAS
32
Show member pathways
11.99 PTEN PIK3CA NRAS EGFR BRAF
33 11.98 TP53 PTEN PIK3CA NRAS
34
Show member pathways
11.98 TP53 PTEN PIK3CA NRAS EGFR BRAF
35 11.93 TP53 PTEN BRAF BMI1
36 11.88 PTPN11 PIK3CA NRAS EGFR
37 11.85 TP53 PTEN PIK3CA
38
Show member pathways
11.79 PIK3CA NRAS BRAF
39 11.71 TP53 NRAS EGFR BRAF
40 11.68 TP53 PTEN PIK3CA
41 11.58 PTPN11 PTEN PIK3CA
42 11.58 TP53 PTEN PIK3CA
43 11.48 TP53 PTEN NRAS MGMT EGFR BRAF
44 11.45 NRAS EGFR BRAF
45 11.38 PIK3CA NRAS EGFR BRAF
46 11.3 TP53 NRAS EGFR
47 11.26 PTEN PIK3CA NRAS
48 11.21 PIK3CA EGFR BRAF
49 11.16 PTPN11 PIK3CA EGFR
50 10.94 TP53 PTEN PIK3CA NRAS IDH1 EGFR

GO Terms for Brain Cancer

Biological processes related to Brain Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 9.93 SMARCB1 PTEN NES EPHB2 ALK
2 peptidyl-tyrosine phosphorylation GO:0018108 9.73 EPHB2 EGFR BRAF ALK
3 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.72 PIK3CA EGFR BRAF
4 cell differentiation GO:0030154 9.72 TP53 SMARCB1 EGFR DMBT1 BRAF
5 cellular response to drug GO:0035690 9.67 TP53 EGFR BRAF
6 learning or memory GO:0007611 9.63 PTEN EPHB2 EGFR
7 epidermal growth factor receptor signaling pathway GO:0007173 9.58 PTPN11 PIK3CA EGFR
8 response to organic cyclic compound GO:0014070 9.56 PTEN MGMT IDH1 EGFR
9 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.52 TP53 EGFR
10 NADP metabolic process GO:0006739 9.51 IDH2 IDH1
11 regulation of axon regeneration GO:0048679 9.48 PTEN BRAF
12 isocitrate metabolic process GO:0006102 9.37 IDH2 IDH1
13 negative regulation of apoptotic process GO:0043066 9.35 TP53 PTEN MGMT EGFR BRAF
14 glyoxylate cycle GO:0006097 9.16 IDH2 IDH1
15 positive regulation of ERK1 and ERK2 cascade GO:0070374 8.92 PTPN11 PTEN EGFR BRAF

Molecular functions related to Brain Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 TP53 PTEN IDH1 EPHB2 EGFR BRAF
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.5 EPHB2 EGFR ALK
3 protein tyrosine kinase activity GO:0004713 9.46 EPHB2 EGFR BRAF ALK
4 insulin receptor substrate binding GO:0043560 9.4 PTPN11 PIK3CA
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.07 PIK3CA
6 isocitrate dehydrogenase activity GO:0004448 8.96 IDH2 IDH1
7 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.62 IDH2 IDH1

Sources for Brain Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....